Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Nationwide Children's Hospital
University of California, San Francisco
University of California, San Francisco
Novartis
Dana-Farber Cancer Institute
Children's Oncology Group
NYU Langone Health
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
University of Iowa
European Organisation for Research and Treatment of Cancer - EORTC
Mayo Clinic
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Tactical Therapeutics, Inc.
University of Iowa
Emory University
National Cancer Institute (NCI)
Northwestern University
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
Candel Therapeutics, Inc.
National Cancer Institute (NCI)
University of Iowa
Celgene
Basilea Pharmaceutica
Sichuan University
Universitätsmedizin Mannheim
Monteris Medical
Northwestern University
Providence Health & Services
National Cancer Institute (NCI)
Northwestern University
Candel Therapeutics, Inc.
Case Comprehensive Cancer Center
Laminar Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
Celgene
Masonic Cancer Center, University of Minnesota
Maastricht Radiation Oncology